These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15281319)

  • 21. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
    Aso Y; Akaza H; Kameyama S; Niijima T
    Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
    [No Abstract]   [Full Text] [Related]  

  • 24. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.
    Lamm DL
    Oncology (Williston Park); 1995 Oct; 9(10):947-52, 955, discussion 955-65. PubMed ID: 8573479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract]   [Full Text] [Related]  

  • 26. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
    Catalona WJ; Ratliff TL
    Surg Annu; 1990; 22():363-78. PubMed ID: 2408170
    [No Abstract]   [Full Text] [Related]  

  • 27. Preventing progression and improving survival with BCG maintenance.
    Lamm DL
    Eur Urol; 2000; 37 Suppl 1():9-15. PubMed ID: 10575266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 33. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?
    Decobert M; LaRue H; Harel F; Meyer F; Fradet Y; Lacombe L
    Cancer; 2008 Aug; 113(4):710-6. PubMed ID: 18543328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
    Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
    Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superficial bladder disease: case studies and therapeutic advances.
    Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
    Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
    [No Abstract]   [Full Text] [Related]  

  • 37. [Topical BCG therapy of in situ cancer of the urinary bladder].
    Mack D; Jakse G
    Urologe A; 1987 Jan; 26(1):22-5. PubMed ID: 3576860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy.
    Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Duvdevani M; Shapiro A
    Urol Oncol; 2009; 27(3):258-62. PubMed ID: 18440839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
    Yamada Y; Hara I; Kumano M; Furukawa J; Yamanaka K; Kamidono S
    Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.